论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
对来那度胺联合疗法在 EBV 阳性弥漫性大B细胞淋巴瘤和血管免疫母细胞性 T 细胞淋巴瘤组成的不一致淋巴瘤中的鼓励 性反应:一病例报告
Authors Hu P, Ben Y, Liu J, Zheng W, Yan X, Zhang Y, Shi W
Received 16 January 2021
Accepted for publication 25 March 2021
Published 12 April 2021 Volume 2021:14 Pages 2489—2495
DOI https://doi.org/10.2147/OTT.S297539
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr William Cho
Abstract: Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) complicated with angioimmunoblastic T-cell lymphoma (AITL) is extremely rare and typically shows an aggressive clinical course and unsatisfactory prognosis. Here, we describe the case of a 77-year-old man who was referred to the hospital because of repeated fever, night sweats, and weight loss. He was finally diagnosed with a discordant lymphoma consisting of AITL and DLBCL, with significantly different maximum standardized uptake values on positron emission tomography/computed tomography. Based on his complex illness and poor performance status, the patient received six cycles of lenalidomide combined with R-miniCHOP regimen and achieved complete remission with tolerable and controlled toxicity. He subsequently received lenalidomide maintenance therapy and achieved sustained remission. We consider the possible causes of this discordance involved AITL and EBV-positive DLBCL, and the possible mechanism of lenalidomide action in both T-cell and B-cell non-Hodgkin lymphomas. Lenalidomide-combination therapy may be a preferable choice in patients with an EBV-associated discordant lymphoma.
Keywords: Epstein–Barr virus, diffuse large B-cell lymphoma, angioimmunoblastic T-cell lymphoma, discordant lymphoma, lenalidomide, positron emission tomography/computed tomography